Skip to main content

Table 3 The pCR rates according to the pathological subtypes

From: Is insulin resistance a predictor for complete response in breast cancer patients who underwent neoadjuvant treatment?

Pathologic subtype Pathological response
CR (n = 16) Non-CR (n = 39)
HR+, HER-2− (n = 31) 8 (25%) 23 (75%)
HR+, HER-2+ (n = 9) 2 (22%) 7 (78%)
HR−, HER-2 + (n = 7) 3 (42%) 4 (58%)
HR−, HER-2− (n = 8) 3 (38%) 5 (62%)
  1. HR hormon receptor, Her-2 human epidermal growth factor receptor 2